GSK recruiting 150 for Costa Rica ops center; Takeda plans $2.7B charge for Actos settlement;

@FiercePharma: $GSK buoyed by early numbers on Anoro, Breo DTC campaigns. More | Follow @FiercePharma

@EricPFierce: Manufacturing plant cost baked into $2.5B Biogen CEO says it will cost to develop Alzheimer's drug. Item | Follow @EricPFierce

@CarlyHFierce: What's in a (drug) name? We asked the #FierceMadness champs. Article | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) said it would hire 150 new workers in Costa Rica to expand its business services operations there. Report

> Takeda Pharmaceutical will take a $2.7 billion charge against fiscal 2014 earnings to cover its $2.4 billion agreement to settle liability cases over its diabetes drug Actos. Report

> Ariad Pharmaceuticals ($ARIA) CEO Harvey Berger will retire as part of a deal with activist investor Sarissa Capital Management. Report

> France's Ipsen said sales rose to 350 million euros in the first quarter, up from 305.9 million euros a year ago, with specialty drug sales up 10% to 12% for the period. Report

> Teva Pharmaceutical ($TEVA) rolled out its version of the injectable thrombin inhibitor Argatroban. Release

Medical Device News

@FierceMedDev: NuVasive gains on $14M DOJ settlement over improper Medicare, Medicaid claims. Story | Follow @FierceMedDev

@VarunSaxena2: Drug testing company Cordant raises $12.8M as it seeks to be fragmented industry's one-stop shop. More | Follow @VarunSaxena2

@EmilyWFierce: #France's Labco looks to make market entree with €545 million IPO. Article | Follow @EmilyWFierce

> Philips ramping up CT scan production following €100M quality improvement plan at Cleveland facility. More

> Kaiser backs startup in $12.5M round to speed healthcare data integration. Story

> NuVasive gains on $14M DOJ settlement over improper Medicare, Medicaid claims. Article

Biotech News

@FierceBiotech: Activists get their way as Ariad CEO Berger steps down. Article | Follow @FierceBiotech

@JohnCFierce: I asked CRISPR Tx CEO Novak if he was prepping an IPO. (Answer: all options open) Felt damn silly even asking, but you have to these days. | Follow @JohnCFierce

@DamianFierce: Zymoquizyme got robbed. RT @CarlyHFierce What's in a (drug) name? We asked the #FierceMadness champs. More | Follow @DamianFierce

> Amgen adding 100 researchers in Cambridge as biotechs scout for 1,000-plus. More

> Celgene bets $30M on a Versant-backed cancer startup. News

> Celgene deepens its Agios ties with an $80M option deal. Story

Biotech Research News

> Mayo Clinic study finds a potential Achilles' heel for HER2-positive cancer. Story

> Better than RNAi? Emory team modifies CRISPR-Cas9 tech for viral infections. News

> Yale collaborators use gene editing tech to fix a cystic fibrosis mutation. Article

> International team opens a 'new frontier' in diabetes research. More

> Google's Calico continues its partnering romp on aging R&D with Buck collaboration. More

Diagnostics News

> Researchers show Adaptive's next-gen sequencing tech can diagnose recurrent Hodgkin lymphoma. Story

> Veracyte unveils $40M private placement to generate cash for R&D. Article

> Biocartis charges ahead with $109M IPO to fuel product development. More

> Drug testing company Cordant raises $12.8M as it seeks to be fragmented industry's one-stop shop. News

> Roche charges ahead with diagnostics R&D after sealing Foundation deal. Report

Pharma Marketing News

> Time for an asthma check, doc? AstraZeneca-sponsored EHR reminders will tell you. More

> GSK buoyed by early numbers on Anoro, Breo DTC campaigns. News

> Merck could be in for big Januvia boost, thanks to 'completely balanced' heart data. Report

> AbbVie says disappointing Viekira sales numbers are misleading. Article

> Pharma earns failing marks for integrity, but it beats advertising. Story

And Finally... Just two weeks of increased high-fructose corn syrup consumption had major--and negative--effects on cholesterol and triglyceride levels, a new study reveals. Report

Suggested Articles

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.